tiprankstipranks

Bio-Rad price target raised to $469 from $446 at RBC Capital

RBC Capital raised the firm’s price target on Bio-Rad (BIO) to $469 from $446 and keeps an Outperform rating on the shares. The company beat EBITDA estimates by over $30M with $4M-$5M coming from higher royalties and the rest of the beat broad based from mix, efficiencies, spending control, and better than expected revenue growth in both segments, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue